Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
2.
Biomed Phys Eng Express ; 8(6)2022 09 07.
Article in English | MEDLINE | ID: mdl-35981496

ABSTRACT

Objective.In this modelling study, we pursued two main goals. The first was to establish a new CTV-to-PTV expansion which considers the closest and most critical organ at risk (OAR). The second goal was to investigate the impact of the planning target volume (PTV) margin size on the tumor control probability (TCP) and its dependence on the geometrical setup uncertainties. The aim was to achieve a smaller margin expansion close to the OAR while allowing a moderately larger expansion in less critical areas further away from the OAR and whilst maintaining the TCP.Approach.Imaging data of radiation therapy plans from pet dogs which had undergone radiation therapy for brain tumor were used to estimate the clinic specific rotational setup uncertainties. A Monte-Carlo methodology using a voxel-based TCP model was used to quantify the implications of rotational setup uncertainties on the TCP. A combination of algorithms was utilized to establish a computational CTV-to-PTV expansion method based on probability density. This was achieved by choosing a center of rotation close to an OAR. All required software modules were developed and integrated into a software package that directly interacts with the Varian Eclipse treatment planning system.Main results.Several uniform and non-isotropic PTVs were created. To ensure comparability and consistency, standardized RT plans with equal optimization constraints were defined, automatically applied and calculated on these targets. The resulting TCPs were then computed, evaluated and compared.Significance.The non-isotropic margins were found to result in larger TCPs with smaller margin excess volume. Further, we presented an additional application of the newly established CTV-to-PTV expansion method for radiation therapy of the spinal axis of human patients.


Subject(s)
Brain Neoplasms , Radiotherapy Planning, Computer-Assisted , Animals , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/radiotherapy , Dogs , Humans , Probability , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Uncertainty
3.
Vet Radiol Ultrasound ; 63(3): e24-e28, 2022 May.
Article in English | MEDLINE | ID: mdl-35306715

ABSTRACT

An 8-year-old, intact Rottweiler-female dog presented due to an acute onset of lethargy, abnormal gait, and wheezing. Physical examination revealed stridor, cervical pain, and ambulatory tetraparesis. Magnetic resonance imaging-examination displayed a lobulated, fluid-filled mass extending from the sphenoid bone to C5, infiltrating the cranial vertebral canal causing extradural compression of the spinal cord and narrowing of the pharynx. An emergency debulking-surgery around the pharynx was performed. Histopathological findings were consistent with a myxoma. The remaining tumor was irradiated resulting in stable disease 6 months later. The dog died 18 months later due to aspiration pneumonia without clinical signs of neurologic or respiratory compromise.


Subject(s)
Dog Diseases , Myxoma , Spinal Cord Compression , Animals , Cervical Vertebrae/diagnostic imaging , Cervical Vertebrae/pathology , Dog Diseases/diagnostic imaging , Dog Diseases/radiotherapy , Dogs , Female , Magnetic Resonance Imaging/veterinary , Myxoma/diagnostic imaging , Myxoma/surgery , Myxoma/veterinary , Spinal Canal/pathology , Spinal Cord Compression/veterinary
4.
Int J Radiat Oncol Biol Phys ; 110(5): 1530-1537, 2021 08 01.
Article in English | MEDLINE | ID: mdl-33838213

ABSTRACT

PURPOSE: Tumor control probability (TCP) models based on Poisson statistics characterize the distribution of surviving clonogens. Thus enabling the calculation of TCP for individuals. To mathematically describe clinically observed survival data of patient cohorts it is necessary to extend the Poisson TCP model. This is typically done by either incorporating variations of model parameters or by using an empirical logistic model. The purpose of this work is the development of an analytical population TCP model by mechanistic extension of the Possion model. METHODS AND MATERIALS: The frequency distribution of gross tumor volumes was used to incorporate tumor volume variations into the TCP model. Additionally the tumor cell density variation was incorporated. Both versions of the population TCP model were fitted to clinical data and compared to existing literature. RESULTS: It was shown that clinically observed brain tumor volumes of dogs undergoing radiotherapy are distributed according to an exponential distribution. The average gross tumor volume size was 3.37 cm3. Fitting the population TCP model including the volume variation using linear-quadratic and track-event model yieldedα=0.36Gy--1a, ß=0.045Gy--2, a=0.9yr--1, TD=5.0d,and p=.36Gy--1, q=0.48Gy--1, a=0.80yr--1, TD=3.0d, respectively. Fitting the population TCP model including both the volume and cell density variation yielded α=0.43Gy--1, ß=0.0537Gy--2, a=2.0yr--1, TD=3.0d, σ=2.5,and p=.43Gy--1, q=0.55Gy--1, a=2.0yr--1, TD=2.0d, σ=3.0,respectively. CONCLUSIONS: Two sets of radiobiological parameters were obtained which can be used for quantifying the TCP for radiation therapy of brain tumors in dogs. We established a mechanistic link between the poisson statistics based individual TCP model and the logistic TCP model. This link can be used to determine the radiobiological parameters of patient specific TCP models from published fits of logistic models to cohorts of patients.


Subject(s)
Brain Neoplasms/veterinary , Dog Diseases/radiotherapy , Models, Statistical , Poisson Distribution , Tumor Burden , Animals , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , Cell Count , Cell Survival , Dog Diseases/mortality , Dog Diseases/pathology , Dogs , Linear Models , Radiation Dose Hypofractionation , Radiobiology
5.
Cell Stress Chaperones ; 24(5): 969-978, 2019 09.
Article in English | MEDLINE | ID: mdl-31375996

ABSTRACT

The concentration of circulating heat shock protein 70 (Hsp70) was measured in liquid biopsies of canine tumor patients as a potential biomarker. Compared with rodent tumor models, spontaneously occurring tumors in pet dogs reflect the clinical situation of human patients better, as dogs cohabitate with their owners in the same environment, reach a much older age than rodents, can provide blood samples much more frequently, and receive up-to-date medical care and, similar to humans, their tumors show a high genetic heterogeneity. Due to the species-specific sequence homology of human and canine Hsp70, two human enzyme-linked immunosorbent assay (ELISA) systems (R&D and lipHsp70) were used to measure canine Hsp70 concentrations in serum and plasma. In general, higher Hsp70 concentrations were found in serum compared with plasma samples of dogs, and the lipHsp70 ELISA detected higher peak concentrations of Hsp70 in a broader range than the R&D ELISA. Compared with a tumor-free control group, serum Hsp70 concentrations were higher in tumor-bearing dogs, irrespective of breed, age, body weight, and gender. A sub-classification of the different tumors according to their cytological characteristics revealed significantly elevated Hsp70 serum concentrations in dogs with round cell tumors (p < 0.01), a heterogeneous group of malignancies with hematopoietic origin such as mast cells, plasma cells, lymphocytes, histiocytes, and melanomas. Future studies with larger patient cohorts and well-defined tumor sizes are necessary to elucidate the role of serum Hsp70 as a biomarker for tumor detection and monitoring of outcome in pet animals.


Subject(s)
Biomarkers, Tumor/blood , HSP70 Heat-Shock Proteins/blood , Neoplasms/metabolism , Animals , Cell Line, Tumor , Dogs , Female , Male
6.
Vet Radiol Ultrasound ; 57(1): 75-83, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26551348

ABSTRACT

Wide surgical resection or a marginal/incomplete resection followed by full-course radiation therapy is the current standard of care for canine soft tissue sarcoma. The purpose of this retrospective, descriptive, bi-institutional study was to determine the effectiveness and toxicity of a hypofractionated 5 × 6 Gy protocol on macroscopic canine soft tissue sarcoma in terms of progression-free interval (PFI) and overall survival (OS), and to identify prognostic factors for patient outcome. Dogs with macroscopic soft tissue sarcoma irradiated with 5 × 6 Gy were eligible for the study. Progression-free interval and OS were compared with respect to different tumor and patient characteristics by the Kaplan-Meier method and multivariable Cox regression analysis. Fifty dogs with macroscopic disease were included. All dogs received the same radiation therapy protocol; part of the group (n = 20) received postradiation metronomic chemotherapy. Median PFI for all cases was 419 days (95% confidence interval (CI): 287-551) and median OS was 513 days (95% CI: 368-658). Dogs with tumors on the limbs had significantly longer PFI and OS, compared with head or trunk. Increasing tumor burden decreased OS. The addition of metronomic chemotherapy yielded a significantly longer OS (757 days (95% CI: 570-944) compared with dogs that did not receive systemic treatment (286 days (95% CI: 0-518), (P = 0.023)), but did not influence progression-free interval. Toxicity was low throughout all treatments. The 5 × 6 Gy radiation therapy protocol was well tolerated and provided long PFI and OS in dogs with macroscopic soft tissue sarcoma.


Subject(s)
Dog Diseases/drug therapy , Dog Diseases/radiotherapy , Sarcoma/veterinary , Administration, Metronomic/veterinary , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacology , Disease Progression , Dogs , Female , Male , Retrospective Studies , Sarcoma/drug therapy , Sarcoma/radiotherapy
7.
Acta Vet Scand ; 57: 4, 2015 Jan 31.
Article in English | MEDLINE | ID: mdl-25637270

ABSTRACT

BACKGROUND: A plethora of treatment options have been described for canine meningoencephalitis of unknown origin (MUO), yet a gold standard has not been established. The aim of this prospective pilot study was to document the effect of a newly designed 30 Gray (Gy) radiation therapy (RT) protocol plus corticosteroids as treatment for focal and multifocal MUO, to monitor clinical and imaging changes during the course of the disease with conventional magnetic resonance imaging (MRI) and proton MR Spectroscopy (H-1 MRS) and to detect the occurrence of radiation related side effects. RESULTS: Six dogs (3 with focal and 3 with multifocal lesions) were included in the study. The RT protocol used consisted of 30 Gy in 10 fractions. The neurological status of all six dogs improved during RT, with 3 of 6 cases returning to a normal condition. One dog was euthanized early during follow-up (<3 weeks after end of RT). Three month follow up MRI was normal in one dog and improved in 3 dogs and H-1 MRS normalized in 4. In the dog without improvement of the MRI lesions, the N-acetyl aspartate continued to decrease, while choline and creatine concentrations remained stable during that time. This dog was euthanized 18 month after the end of RT due to relapse. One dog was lost to follow up 12 month after completion of RT. The other 3 dogs are still alive at the time of writing. CONCLUSIONS: RT with 30 Gy in 10 fractions can provide an additional option for anti-inflammatory treatment of focal and multifocal MUO. The protocol used for treatment monitoring was feasible while no side effects of RT could be observed during the follow up period. Moreover, H-1 MRS could represent a new and non-invasive tool to control the progression of the disease during the treatment course.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Dog Diseases/drug therapy , Dog Diseases/radiotherapy , Magnetic Resonance Spectroscopy/methods , Meningoencephalitis/veterinary , Prednisolone/therapeutic use , Radiotherapy/veterinary , Animals , Dog Diseases/etiology , Dogs , Female , Male , Meningoencephalitis/drug therapy , Meningoencephalitis/etiology , Meningoencephalitis/radiotherapy , Pilot Projects , Prospective Studies
8.
Vet Clin Pathol ; 42(1): 47-54, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23278475

ABSTRACT

A 12-year-old, spayed female, mixed-breed dog was presented for acute hematuria, stranguria, polyuria, and polydipsia, as well as lameness for 8 days. Previous medical history included treatment for infection with Ehrlichia canis, Anaplasma phagocytophilum, Leishmania infantum, and Dirofilaria immitis 6.5 years prior to presentation. Besides persistently increased antibody titers to E canis and A phagocytophilum, polyclonal gammopathy with a monoclonal spike and moderate hypercalcemia were observed. There was marked hematuria, and Staphylococcus aureus was cultured from urine. Two weeks after successful treatment of the urinary tract infection, radiographs showed an extensive destructive monostotic lesion of the right humerus. Cytologic examination of fine-needle aspirates of this lesion revealed a neoplastic round cell population suggestive of multiple myeloma. The dog was treated with melphalan and prednisolone for suspected multiple myeloma and doxycycline for suspected ehrlichiosis and anaplasmosis. Treatments lead to resolution of the clinical signs, hypercalcemia, and monoclonal gammopathy, and there was radiographic improvement of bone lesions; polyclonal gammopathy persisted. About one year after presentation the dog was still in clinical remission. This is a rare report of a dog with suspected multiple myeloma and a history of multiple chronic infectious diseases, suggesting that chronic infection and uncontrolled long-term stimulation of the immune system could contribute to the pathogenesis of multiple myeloma.


Subject(s)
Dog Diseases/pathology , Multiple Myeloma/veterinary , Anaplasma phagocytophilum , Animals , Anti-Bacterial Agents/therapeutic use , Antineoplastic Agents/therapeutic use , Diagnosis, Differential , Dog Diseases/diagnosis , Dog Diseases/drug therapy , Dogs , Ehrlichia canis , Ehrlichiosis/complications , Ehrlichiosis/drug therapy , Ehrlichiosis/veterinary , Female , Leishmania infantum , Leishmaniasis, Visceral/complications , Leishmaniasis, Visceral/veterinary , Multiple Myeloma/complications , Multiple Myeloma/drug therapy , Multiple Myeloma/pathology , Staphylococcal Infections/complications , Staphylococcal Infections/microbiology , Staphylococcal Infections/veterinary , Urinary Tract Infections/complications , Urinary Tract Infections/microbiology , Urinary Tract Infections/veterinary
9.
BMC Vet Res ; 8: 72, 2012 May 30.
Article in English | MEDLINE | ID: mdl-22647582

ABSTRACT

BACKGROUND: Mammary tumors represent the most common neoplastic disease in female dogs. Recently, the promoting role of prolactin (PRL) in the development of human breast carcinoma has been shown. Possible proliferative, anti-apoptotic, migratory and angiogenic effects of PRL on human mammary cancer cells in vitro and in vivo were suggested. The effects of PRL are mediated by its receptor, and alterations in receptor expression are likely to play a role in tumor development. Currently, not much data is available about prolactin receptor (PRLR) expression in canine mammary tumors. To set the basis for investigations on the role of PRL in mammary tumorigenesis in this species, prolactin receptor expression was evaluated by semi-quantitative real time PCR and immunohistochemistry on 10 formalin-fixed, paraffin-embedded samples each of canine non-neoplastic mammary tissue, mammary adenomas and adenocarcinomas. RESULTS: The highest PRLR expression levels were found in normal mammary tissue, while adenomas, and to an even higher degree adenocarcinomas, showed a significant decrease in prolactin receptor expression. Compared to normal tissue, PRLR mRNA was reduced 2.4 fold (p = 0.0261) in adenomas and 4.8 fold (p = 0.008) in adenocarcinomas. PRLR mRNA expression was significantly lower in malignant than in benign lesions (p = 0.0165). Immunohistochemistry demonstrated PRLR expression in all three tissue types with signals mostly limited to epithelial cells. CONCLUSIONS: Malignant transformation of mammary tissue was associated with a decline in prolactin receptor expression. Further studies are warranted to address the functional significance of this finding.


Subject(s)
Adenocarcinoma/veterinary , Adenoma/veterinary , Dog Diseases/metabolism , Mammary Glands, Animal/metabolism , Mammary Neoplasms, Animal/metabolism , Receptors, Prolactin/metabolism , Adenocarcinoma/metabolism , Adenoma/metabolism , Animals , Dogs , Down-Regulation , Female , Gene Expression Regulation, Neoplastic/physiology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Prolactin/genetics
10.
Vet J ; 186(1): 58-63, 2010 Oct.
Article in English | MEDLINE | ID: mdl-19692273

ABSTRACT

Radiation therapy does not only target tumour cells but also affects tumour vascularity. In the present study, changes in tumour vascularity and blood volume were investigated in five grade 1 oral fibrosarcomas, eight other sarcomas (non-oral soft tissue and bone sarcomas) and 12 squamous cell carcinomas in dogs during fractionated radiation therapy (total dose, 45-56 Gy). Contrast-enhanced power Doppler ultrasound was performed before fraction 1, 3, 6, 8, 10, 12, 14 and 15 or 16 (sarcomas) or 17 (squamous cell carcinomas). Prior to treatment, median vascularity and blood volume were significantly higher in squamous cell carcinomas (P=0.0005 and 0.001), whereas measurements did not differ between oral fibrosarcomas and other sarcomas (P=0.88 and 0.999). During the course of radiation therapy, only small, non-significant changes in vascularity and blood volume were observed in all three tumour histology groups (P=0.08 and P=0.213), whereas median tumour volume significantly decreased until the end of treatment (P=0.04 for fibrosarcomas and other sarcomas, P=0.008 for squamous cell carcinomas). It appeared that there was a proportional decrease in tumour volume, vascularity and blood volume. Doppler measurements did not predict progression free interval or survival in any of the three tumour groups (P=0.06-0.86). However, the number of tumours investigated was small and therefore, the results can only be considered preliminary.


Subject(s)
Carcinoma, Squamous Cell/veterinary , Dog Diseases/radiotherapy , Mouth Neoplasms/veterinary , Sarcoma/veterinary , Ultrasonography, Doppler, Color/veterinary , Animals , Blood Volume/radiation effects , Blood Volume/veterinary , Bone Neoplasms/blood supply , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/radiotherapy , Bone Neoplasms/veterinary , Carcinoma, Squamous Cell/blood supply , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/radiotherapy , Contrast Media , Dog Diseases/diagnostic imaging , Dogs , Female , Fibrosarcoma/blood supply , Fibrosarcoma/diagnostic imaging , Fibrosarcoma/radiotherapy , Fibrosarcoma/veterinary , Image Enhancement , Male , Mouth Neoplasms/blood supply , Mouth Neoplasms/diagnostic imaging , Mouth Neoplasms/radiotherapy , Regional Blood Flow/radiation effects , Sarcoma/blood supply , Sarcoma/diagnostic imaging , Sarcoma/radiotherapy , Treatment Outcome , Ultrasonography, Doppler, Color/methods
11.
Vet J ; 183(1): 58-62, 2010 Jan.
Article in English | MEDLINE | ID: mdl-18922713

ABSTRACT

Conventionally, tumour vascularity is assessed invasively by immunofluorescent analysis. Quantified contrast-enhanced power Doppler ultrasound has been used to measure tumour angiogenesis non-invasively in humans and experimental animals. The purpose of this study was to correlate quantified contrast-enhanced power Doppler ultrasound with immunofluorescent results in 45 spontaneous canine tumours. With power Doppler, mean vascularity was high in squamous cell carcinomas, moderate in malignant oral melanomas and low in sarcomas. There was high mean vascularity in squamous cell carcinomas and low mean vascularity in sarcomas and malignant oral melanomas. Although Doppler parameters correlated moderately with microvascular density for all tumours (P=0.004, r=0.4), they did not correlate within histology groups. These analyses show that vascularity differs among canine tumour histology groups. However, dependent on the method used, measurement of tumour vascularity can provide different biological information.


Subject(s)
Dog Diseases/diagnostic imaging , Neoplasms/veterinary , Neovascularization, Pathologic/veterinary , Ultrasonography, Doppler/veterinary , Animals , Contrast Media , Dogs , Female , Fluorescent Antibody Technique/veterinary , Male , Neoplasms/blood supply , Neoplasms/diagnostic imaging , Neovascularization, Pathologic/diagnostic imaging , Neovascularization, Pathologic/pathology , Ultrasonography, Doppler, Color/veterinary
12.
Vet Radiol Ultrasound ; 50(6): 679-83, 2009.
Article in English | MEDLINE | ID: mdl-19999357

ABSTRACT

We evaluated the response of 38 dogs treated with a coarsely fractionated, palliative radiation protocol based on CT-based 3D treatment planning. Dogs with histologically confirmed malignant nasal tumors were studied. Treatment prescriptions consisted of 3-4 x 8 Gy, 4-5 x 6 Gy, or 10 x 3 Gy fractions. Selected patient and tumor factors were evaluated for an effect on outcome. Resolution of clinical signs was reported after irradiation in all dogs. Acute toxicities were mild and short lived. Thirty-seven of 38 dogs died or were euthanized due to tumor-related disease. Overall median progression-free interval (PFI) was 10 months. Tumor stage affected response, with modified stage 1 patients having a median PFI 21.3 months vs. a median PFI of 8.5 months for modified stage 2 patients (P = 0.0006). Modified stage was the only factor significantly related to outcome. Based on these findings, a palliative radiation prescription based on computerized treatment planning may be justified in some canine nasal tumor patients.


Subject(s)
Dog Diseases/radiotherapy , Nose Neoplasms/veterinary , Animals , Dog Diseases/mortality , Dogs , Euthanasia, Animal , Neoplasm Metastasis , Neoplasm Staging/veterinary , Nose Neoplasms/mortality , Nose Neoplasms/radiotherapy , Palliative Care/methods , Radiation Dosage , Survival Analysis , Treatment Outcome
14.
Clin Cancer Res ; 15(4): 1335-42, 2009 Feb 15.
Article in English | MEDLINE | ID: mdl-19228735

ABSTRACT

PURPOSE: The combined treatment modality of ionizing radiation (IR) and the clinically relevant microtubule-stabilizing compound patupilone (epothilone B, EPO906) is a promising approach for anticancer therapy. Here, we investigated the role of the tumor microenvironment for the supra-additive in vivo response in tumor xenografts derived from patupilone-sensitive and patupilone-resistant non-small cell lung cancer cells. EXPERIMENTAL DESIGN: The treatment response to a combined regimen of patupilone and IR was investigated in vitro and in tumor xenografts derived from wild-type A549 and A549.EpoB40 cells, which are resistant to patupilone due to a beta-tubulin mutation. RESULTS: In both A549 and A549.EpoB40 cells, proliferative activity and clonogenicity were reduced in response to IR, whereas patupilone, as expected, inhibited proliferation of the mutant cell line with reduced potency. Combined treatment with patupilone and IR induced a cytotoxic effect in vitro in an additive way in A549 cells but not in the tubulin-mutated, patupilone-resistant A549.EpoB40 cells. A supra-additive tumor growth delay was induced by combined treatment in xenografts derived from A549 cells but not in xenografts derived from A549.EpoB40 cells. Histologic analysis revealed a significant decrease in tumor cell proliferation (Ki-67) and microvessel density and a treatment-dependent change of tumor hypoxia in A549 but not A549.EpoB40 xenografts. CONCLUSIONS: Using a genetically defined patupilone-sensitive and patupilone-resistant tumor model, we here showed that the major cytotoxic effect of the combined treatment modality of IR and patupilone is directed against the tumor cell compartment. The induced antiangiogenic effect derives indirectly from the tumor cell.


Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Epothilones/pharmacology , Lung Neoplasms/therapy , Radiation-Sensitizing Agents/pharmacology , Animals , Carcinoma, Non-Small-Cell Lung/blood supply , Carcinoma, Non-Small-Cell Lung/pathology , Cell Hypoxia , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Humans , Lung Neoplasms/blood supply , Lung Neoplasms/pathology , Mice , Neovascularization, Pathologic/therapy , Xenograft Model Antitumor Assays
15.
Vet Dermatol ; 19(6): 321-39, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18980632

ABSTRACT

Mast cells (MCs) are well known for their neoplastic transformation in solitary and multiple cutaneous mast cell tumours (MCTs), as well as visceral and systemic mastocytosis. Dogs have a unique risk of developing cutaneous MCTs, and they account for 7% to 21% of all canine skin tumours. The aetiology of canine MCTs is unknown but is probably multifactorial. This article reviews up-to-date knowledge on the pathogenesis, the clinical presentation, the clinical prognostic factors, the diagnostic workup including clinical staging, cytological findings, histological findings and the various grading systems which have been evaluated based on morphology, the assessment of proliferation markers and other factors such as vessel density. Furthermore, detailed information about current treatment protocols for canine cutaneous MCTs is provided.


Subject(s)
Dog Diseases/pathology , Mastocytoma/veterinary , Animals , Dog Diseases/therapy , Dogs , Mastocytoma/pathology
16.
J Am Vet Med Assoc ; 231(9): 1347-53, 2007 Nov 01.
Article in English | MEDLINE | ID: mdl-17975992

ABSTRACT

OBJECTIVE: To assess the effects of repeated episodes of propofol-associated anesthesia on quality of recovery from anesthesia, clinical status, and erythrocyte physiology in cats. DESIGN: Original study. ANIMALS: 37 cats undergoing short-duration anesthesia for radiotherapy. PROCEDURES: Twice daily on 5 consecutive days, 13 cats with squamous cell carcinoma of the nasal planum (group 1) underwent anesthesia: first via administration of propofol or a midazolam (0.2 mg/kg [0.09 mg/lb])-propofol combination and then via administration of ketamine and midazolam each day (latter data were not analyzed). During a 19-day period, 24 cats with vaccine associated sarcoma (group 2) were anesthetized 12 times with propofol or a midazolam-propofol combination. Anesthesia was maintained with propofol in both groups. Hematologic analysis was performed before, during, and on completion of radiotherapy; changes in Hct and hemoglobin concentration between groups were compared. RESULTS: Mean duration of anesthesia was 8.1 minutes (range, 5 to 20 minutes); no adverse events were detected during recovery. Total dose of propofol administered did not differ between groups 1 (6.34 mg/kg [2.88 mg/lb]) and 2 (4.71 mg/kg [2.14 mg/lb]). Midazolam administration decreased the propofol dose by 26%. Overall decreases from baseline in Hct and hemoglobin concentration were not significantly different between the 2 groups, nor clinically important; however, compared with baseline, values in group 2 were significantly lower after 6 and 12 anesthetic episodes for both protocols. Heinz bodies were identified in low numbers in both groups during radiotherapy. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that repeated propofol-associated short-duration anesthesia does not lead to clinically relevant hematologic changes in cats undergoing short-duration radiotherapy.


Subject(s)
Anesthesia, Intravenous/veterinary , Anesthetics, Intravenous/administration & dosage , Cats/physiology , Hematocrit/veterinary , Hemoglobins/analysis , Propofol/administration & dosage , Anesthesia, Intravenous/adverse effects , Anesthesia, Intravenous/methods , Anesthetics, Intravenous/adverse effects , Animals , Blood Pressure/drug effects , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/veterinary , Cat Diseases/radiotherapy , Cats/blood , Drug Combinations , Female , Heinz Bodies , Ketamine/administration & dosage , Male , Midazolam/administration & dosage , Nose Neoplasms/radiotherapy , Nose Neoplasms/veterinary , Propofol/adverse effects , Sarcoma/radiotherapy , Sarcoma/veterinary , Treatment Outcome , Vaccination/adverse effects , Vaccination/veterinary
17.
J Vet Intern Med ; 21(4): 770-5, 2007.
Article in English | MEDLINE | ID: mdl-17708398

ABSTRACT

BACKGROUND: Squamous cell carcinomas are common skin tumors in cats. We investigated photodynamic therapy (PDT) using a new liposomal photosensitizer as a minimally invasive, effective treatment that can be easily performed while achieving good cosmetic results. AIM: The goal of this study was to assess and describe possible toxicities using a liposomal formulation of the photosensitizer meta-(Tetrahydroxyphenyl)Chlorin (m-THPC) and investigate if favorable pharmacokinetics translate into favorable tumor response and control. ANIMALS: Eighteen client-owned cats with 20 spontaneous cutaneous squamous cell carcinomas were included in the study. METHODS: PDT was performed using a new, liposomal formulation of the photosensitizer. Toxicity, tumor response, and tumor control were evaluated retrospectively. RESULTS: No general adverse effects were observed in cats treated with the new liposomal formulation. Mild local toxicity such as erythema and edema were seen in 15% of the patients. All cats responded to therapy, with a complete response rate of 100%. The overall 1-year control rate was 75%. The tumor recurrence rate was 20% with a median time to recurrence of 172.25 +/-87.1) days. CONCLUSIONS AND CLINICAL IMPORTANCE: A new liposomal photosensitizer was successfully used for squamous cell carcinoma in cats and was well tolerated. There were no systemic adverse effects observed with the liposomal formulation. The favorable pharmacokinetics of the liposomal drug resulted in a favorable tumor response.


Subject(s)
Carcinoma, Squamous Cell/veterinary , Cat Diseases/therapy , Mesoporphyrins/administration & dosage , Mesoporphyrins/therapeutic use , Photochemotherapy/veterinary , Skin Neoplasms/veterinary , Animals , Carcinoma, Squamous Cell/therapy , Cats , Chemistry, Pharmaceutical , Liposomes , Mesoporphyrins/adverse effects , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/adverse effects , Photosensitizing Agents/therapeutic use , Skin Neoplasms/therapy , Vascular Endothelial Growth Factor A/blood
18.
Vet J ; 173(3): 564-70, 2007 May.
Article in English | MEDLINE | ID: mdl-17449301

ABSTRACT

PTK787/ZK 222584 is an inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinases. In this study, the effectiveness of PTK787/ZK 222584 and radiation on canine oral melanoma xenografts was assessed. Xenografts were treated with radiotherapy (4x6Gy), or with PTK787/ZK 222584, or with a combination of both. Treatment efficacy was assessed using a tumour growth delay assay, serial power Doppler and pO(2) measurements during and after therapy. There was a significant growth delay for the group treated with radiation alone and for the combined treatment group. However, tumour growth delay was similar in both groups. Tumours were hypoxic before irradiation and no significant re-oxygenation occurred during therapy. In all tumours, vascularity and perfusion were significantly lower at the end of the study but no significant differences in perfusion, vascularity and oxygenation status were observed between and within treatment groups. The combination of PTK787/ZK 222584 and radiotherapy did not perform better than radiotherapy alone in this model.


Subject(s)
Enzyme Inhibitors/therapeutic use , Melanoma/veterinary , Mouth Neoplasms/veterinary , Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors , Animals , Combined Modality Therapy , Dogs , Female , Melanoma/diagnostic imaging , Melanoma/drug therapy , Melanoma/radiotherapy , Mice , Mice, Nude , Mouth Neoplasms/diagnostic imaging , Mouth Neoplasms/drug therapy , Mouth Neoplasms/radiotherapy , Radiotherapy, Adjuvant , Rats , Treatment Outcome , Ultrasonography, Doppler/methods , Ultrasonography, Doppler/veterinary , Vascular Endothelial Growth Factors/metabolism , Xenograft Model Antitumor Assays/veterinary
19.
In Vivo ; 20(3): 415-9, 2006.
Article in English | MEDLINE | ID: mdl-16724681

ABSTRACT

This retrospective study evaluated the efficacy of radiotherapy used alone in macroscopic oral soft tissue sarcoma. Thirty-one dogs qualified for the study. Twenty dogs received curative radiotherapy (median total dose: 52.5 Gy) and eleven dogs were treated palliatively (3 x 8 Gy or 5 x 6 Gy). The time-to-progression for the curatively-treated dogs was 333 days versus 180 days for the palliatively-treated dogs (p=0.134). The overall survival was 331 days for the curative group and 310 days for the palliative group (p =0.2292). The results of this study suggest that radiation therapy is useful in the treatment of oral soft tissue sarcoma.


Subject(s)
Dog Diseases/pathology , Dog Diseases/radiotherapy , Mouth Neoplasms/radiotherapy , Mouth Neoplasms/veterinary , Sarcoma/radiotherapy , Sarcoma/veterinary , Animals , Dog Diseases/mortality , Dogs , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Female , Follow-Up Studies , Male , Mouth Neoplasms/mortality , Mouth Neoplasms/pathology , Retrospective Studies , Sarcoma/mortality , Sarcoma/pathology , Survival Analysis , Time Factors
20.
Avian Dis ; 50(4): 641-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17274308

ABSTRACT

This report describes a case of Mycobacterium tuberculosis infection in a green-winged macaw (Ara chloroptera), confirmed by microbiologic and pathologic diagnostics, and notes a possible human-avian transmission. Clinical signs included cutaneous swellings, profound leukocytosis, and signs of osteomyelitis in the long bones. Proliferation consisted of several nodules with small greenish-caseous foci in cross-section and revealed a severe granulomatous inflammation with intralesional acid-fast rods. Mycobacterium tuberculosis was isolated from subcutaneous nodules and biochemically confirmed. The disease in avian species is of zoonotic importance.


Subject(s)
Bird Diseases/microbiology , Bird Diseases/transmission , Mycobacterium tuberculosis/isolation & purification , Parrots/microbiology , Tuberculosis/transmission , Tuberculosis/veterinary , Animals , Bird Diseases/diagnosis , Bird Diseases/pathology , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...